{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:56:52Z","timestamp":1792792612364,"version":"4.5.0"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fujian Medical University QiHang fund","award":["2019QH1167"],"award-info":[{"award-number":["2019QH1167"]}]},{"name":"Fujian Medical University QiHang fund","award":["2019QH1185"],"award-info":[{"award-number":["2019QH1185"]}]},{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","award":["2022QNA003"],"award-info":[{"award-number":["2022QNA003"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Planning Project of Fujian Provincial Health Commission","award":["2020GGA002"],"award-info":[{"award-number":["2020GGA002"]}]},{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["2020J05264"],"award-info":[{"award-number":["2020J05264"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["2023J011210"],"award-info":[{"award-number":["2023J011210"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The principal therapeutic agents for minimal hepatic encephalopathy (MHE), which focus on the modulation of the gut microbiota, include lactulose and rifaximin; however, the precise mechanisms through which they operate remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aimed to investigate the effects of rifaximin and lactulose on the gut-liver-brain axis in a rat model of MHE and to clarify the underlying mechanisms involved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A rat model of MHE was established by subcutaneous carbon tetrachloride (CCl4) injection. The Morris water maze (MWM) test was used to assess cognitive function in MHE rats following treatment with rifaximin and lactulose. Serum and cerebrospinal fluid ammonia levels were quantified, along with measurements of portal lipopolysaccharide (LPS) and various serum inflammatory markers. Furthermore, the expression of Toll-like receptor 4 (TLR4) in the liver was examined by histopathological evaluation. Additional analyses included the detection of tight junction proteins in the intestinal mucosa as well as colon fecal 16S rRNA sequencing and metabolic pathway assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both rifaximin and lactulose were effective in reducing ammonia concentrations in MHE rats and ameliorating cognitive deficits, although they exhibited a minimal impact on hepatic function. Post-treatment assessments revealed significant reductions in portal LPS, serum interleukin-1\u03b2 (IL-1\u03b2), and tumor necrosis factor-\u03b1 (TNF-\u03b1). The expression of TLR4 in the liver and hepatic inflammatory infiltration were notably diminished. Rifaximin administration led to increased occludin expression in the intestinal tissues of MHE rats. Despite no significant alterations in the diversity or composition of the gut microbiota, metabolic pathway analyses indicated a downregulation of glycometabolism pathways following treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rifaximin and lactulose may enhance cognitive performance in MHE rats by modulating gut microbiota metabolism and preserving the intestinal barrier integrity. This modulation is associated with lowered ammonia levels, decreased translocation of LPS to the liver, and reduced inflammatory response, both in the liver and systemically.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0325988","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T13:32:25Z","timestamp":1750167145000},"page":"e0325988","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["The effects of rifaximin and lactulose on the gut-liver-brain axis in rats with minimal hepatic encephalopathy"],"prefix":"10.1371","volume":"20","author":[{"given":"Xueyan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengchao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9646-0938","authenticated-orcid":true,"given":"Rongrong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"issue":"3","key":"pone.0325988.ref001","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jhep.2022.06.001","article-title":"EASL clinical practice guidelines on the management of hepatic encephalopathy","volume":"77","author":"European Association for the Study of the Liver","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"pone.0325988.ref002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1055\/a-1010-6974","article-title":"Management of hepatic encephalopathy in Germany: a survey among physicians","volume":"58","author":"C Labenz","year":"2020","journal-title":"Z Gastroenterol"},{"issue":"3","key":"pone.0325988.ref003","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jceh.2015.06.008","article-title":"Management patterns of hepatic encephalopathy: a nationwide survey in India","volume":"5","author":"P Sharma","year":"2015","journal-title":"J Clin Exp Hepatol"},{"issue":"2","key":"pone.0325988.ref004","first-page":"151","article-title":"The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies","volume":"31","author":"L Ridola","year":"2018","journal-title":"Ann Gastroenterol"},{"issue":"30","key":"pone.0325988.ref005","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.3748\/wjg.v19.i30.4984","article-title":"Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China","volume":"19","author":"J-Y Wang","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"23","key":"pone.0325988.ref006","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.3748\/wjg.14.3609","article-title":"Minimal hepatic encephalopathy matters in daily life","volume":"14","author":"JS Bajaj","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"3","key":"pone.0325988.ref007","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/apt.14824","article-title":"Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients","volume":"48","author":"C Labenz","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"pone.0325988.ref008","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jhep.2018.12.031","article-title":"The psychomotor vigilance task: role in the diagnosis of hepatic encephalopathy and relationship with driving ability","volume":"70","author":"C Formentin","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"pone.0325988.ref009","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/hep.510310107","article-title":"Partial pressure of ammonia versus ammonia in hepatic encephalopathy","volume":"31","author":"L Kramer","year":"2000","journal-title":"Hepatology"},{"issue":"8","key":"pone.0325988.ref010","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/gut.2007.122176","article-title":"Pathogenetic mechanisms of hepatic encephalopathy","volume":"57","author":"D H\u00e4ussinger","year":"2008","journal-title":"Gut"},{"issue":"6","key":"pone.0325988.ref011","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1440-1746.2010.06318.x","article-title":"Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for study of the liver","volume":"25","author":"RK Dhiman","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"pone.0325988.ref012","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jama.2014.2398","article-title":"Serum ammonia level for the evaluation of hepatic encephalopathy","volume":"312","author":"PS Ge","year":"2014","journal-title":"JAMA"},{"key":"pone.0325988.ref013","doi-asserted-by":"crossref","first-page":"26800","DOI":"10.1038\/srep26800","article-title":"Impaired gut-liver-brain axis in patients with cirrhosis","volume":"6","author":"V Ahluwalia","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"pone.0325988.ref014","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/hep.27819","article-title":"Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy","volume":"62","author":"JS Bajaj","year":"2015","journal-title":"Hepatology"},{"issue":"46","key":"pone.0325988.ref015","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.3748\/wjg.v18.i46.6693","article-title":"Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota","volume":"18","author":"M Garcovich","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"6","key":"pone.0325988.ref016","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.cgh.2014.01.022","article-title":"Hepatic encephalopathy involves interactions among the microbiota, gut, brain","volume":"12","author":"3rd Victor DW","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"pone.0325988.ref017","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4161\/gmic.25723","article-title":"Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship","volume":"4","author":"JM Ridlon","year":"2013","journal-title":"Gut Microbes"},{"issue":"12","key":"pone.0325988.ref018","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.cgh.2015.06.039","article-title":"Covert and overt hepatic encephalopathy: diagnosis and management","volume":"13","author":"KR Patidar","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"pone.0325988.ref019","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s11011-016-9944-5","article-title":"Sleep disturbances in patients of liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy","volume":"32","author":"J Singh","year":"2017","journal-title":"Metab Brain Dis"},{"issue":"4","key":"pone.0325988.ref020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060042","article-title":"Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy","volume":"8","author":"JS Bajaj","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"pone.0325988.ref021","first-page":"9996","article-title":"Probiotic and lactulose: influence on gastrointestinal flora and pH value in minimal hepatic encephalopathy rats","volume":"8","author":"SM Jiang","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"8","key":"pone.0325988.ref022","article-title":"Rifaximin exerts beneficial effects independent of its ability to alter microbiota composition","volume":"7","author":"DJ Kang","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"pone.0325988.ref023","doi-asserted-by":"crossref","first-page":"761192","DOI":"10.3389\/fcimb.2021.761192","article-title":"Rifaximin modulates the gut microbiota to prevent hepatic encephalopathy in liver cirrhosis without impacting the resistome","volume":"11","author":"X Yu","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"38","key":"pone.0325988.ref024","doi-asserted-by":"crossref","first-page":"6983","DOI":"10.3748\/wjg.v23.i38.6983","article-title":"Fecal microbiota transplantation prevents hepatic encephalopathy in rats with carbon tetrachloride-induced acute hepatic dysfunction","volume":"23","author":"W-W Wang","year":"2017","journal-title":"World J Gastroenterol"},{"key":"pone.0325988.ref025","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bbr.2015.01.042","article-title":"Role of dopaminergic and serotonergic neurotransmitters in behavioral alterations observed in rodent model of hepatic encephalopathy","volume":"286","author":"S Dhanda","year":"2015","journal-title":"Behav Brain Res"},{"issue":"1","key":"pone.0325988.ref026","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/s41598-017-02101-8","article-title":"Oral administration of trace element magnesium significantly improving the cognition and locomotion in hepatic encephalopathy rats","volume":"7","author":"Y Li","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"pone.0325988.ref027","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3748\/wjg.v11.i6.908","article-title":"Comparison of probiotics and lactulose in the treatment of minimal hepatic encephalopathy in rats","volume":"11","author":"L Jia","year":"2005","journal-title":"World J Gastroenterol"},{"issue":"3","key":"pone.0325988.ref028","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/liv.12921","article-title":"Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy","volume":"36","author":"SS Sidhu","year":"2016","journal-title":"Liver Int"},{"issue":"5","key":"pone.0325988.ref029","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4166\/kjg.2017.70.5.239","article-title":"Effect of rifaximin on hepatic fibrosis in bile duct-ligated rat model","volume":"70","author":"SK Shin","year":"2017","journal-title":"Korean J Gastroenterol"},{"key":"pone.0325988.ref030","doi-asserted-by":"crossref","first-page":"1091167","DOI":"10.3389\/fmicb.2023.1091167","article-title":"Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota","volume":"14","author":"M-W Wang","year":"2023","journal-title":"Front Microbiol"},{"issue":"5","key":"pone.0325988.ref031","first-page":"767","article-title":"Effects of lactulose on intestinal endotoxin and bacterial translocation in cirrhotic rats","volume":"116","author":"S Zhang","year":"2003","journal-title":"Chin Med J (Engl)"},{"key":"pone.0325988.ref032","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/apt.13435","article-title":"Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis","volume":"43","author":"JS Bajaj","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"pone.0325988.ref033","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13270","article-title":"Peripheral inflammation induces neuroinflammation that alters neurotransmission and cognitive and motor function in hepatic encephalopathy: underlying mechanisms and therapeutic implications","volume":"226","author":"A Cabrera-Pastor","year":"2019","journal-title":"Acta Physiol (Oxf)"},{"issue":"4","key":"pone.0325988.ref034","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jhep.2011.11.013","article-title":"Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice","volume":"56","author":"Q Zhu","year":"2012","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0325988.ref035","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3390\/biomedicines10061263","article-title":"Rifaximin improves spatial learning and memory impairment in rats with liver damage-associated neuroinflammation","volume":"10","author":"P Leone","year":"2022","journal-title":"Biomedicines"},{"issue":"9","key":"pone.0325988.ref036","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.4103\/1673-5374.165516","article-title":"Lactulose enhances neuroplasticity to improve cognitive function in early hepatic encephalopathy","volume":"10","author":"N Yang","year":"2015","journal-title":"Neural Regen Res"},{"issue":"2","key":"pone.0325988.ref037","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/jgh.13841","article-title":"Beneficial effects of rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota","volume":"33","author":"Y Jin","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"pone.0325988.ref038","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.dld.2022.04.012","article-title":"Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis","volume":"54","author":"M Enomoto","year":"2022","journal-title":"Dig Liver Dis"},{"key":"pone.0325988.ref039","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bbi.2019.12.004","article-title":"Gastrointestinal (non-systemic) antibiotic rifaximin differentially affects chronic stress-induced changes in colon microbiome and gut permeability without effect on behavior","volume":"84","author":"D Kuti","year":"2020","journal-title":"Brain Behav Immun"},{"issue":"10","key":"pone.0325988.ref040","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/ajg.2013.221","article-title":"Large-scale survey of gut microbiota associated with MHE via 16S rRNA-based pyrosequencing","volume":"108","author":"Z Zhang","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"pone.0325988.ref041","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/1751-2980.12816","article-title":"Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: a multicenter, randomized controlled trial","volume":"20","author":"JY Wang","year":"2019","journal-title":"J Dig Dis"},{"issue":"6","key":"pone.0325988.ref042","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/liv.14437","article-title":"Cognition and hospitalizations are linked with salivary and faecal microbiota in cirrhosis cohorts from the USA and Mexico","volume":"40","author":"JS Bajaj","year":"2020","journal-title":"Liver Int"},{"issue":"4","key":"pone.0325988.ref043","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11011-014-9507-6","article-title":"Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis","volume":"29","author":"V Ahluwalia","year":"2014","journal-title":"Metab Brain Dis"},{"issue":"8","key":"pone.0325988.ref044","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/ejcn.2012.63","article-title":"Serum fatty-acid composition and the risk of Alzheimer\u2019s disease: a longitudinal population-based study","volume":"66","author":"E R\u00f6nnemaa","year":"2012","journal-title":"Eur J Clin Nutr"},{"issue":"10","key":"pone.0325988.ref045","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrendo.2015.128","article-title":"Short-chain fatty acids in control of body weight and insulin sensitivity","volume":"11","author":"EE Canfora","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"pone.0325988.ref046","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrmicro1836","article-title":"Inter-kingdom signalling: communication between bacteria and their hosts","volume":"6","author":"DT Hughes","year":"2008","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"pone.0325988.ref047","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPAR\u03b3 signaling and metabolism: the good, the bad and the future","volume":"19","author":"M Ahmadian","year":"2013","journal-title":"Nat Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325988","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T13:32:48Z","timestamp":1750167168000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325988"}},"subtitle":[],"editor":[{"given":"Wan-Long","family":"Chuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0325988","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]}}}